Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Zhang, Bo ^a   McDaniel, Sharon S ^a   Rensing, Nicholas R ^a   Wong, Michael ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; VIGABATRIN;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GLIA CELL; IN VIVO STUDY; MOUSE; NERVE CELL CULTURE; NONHUMAN; SIGNAL TRANSDUCTION; SURVIVAL; TUBEROUS SCLEROSIS;

ANIMALS; ANTICONVULSANTS; ASTROCYTES; BRAIN; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, KNOCKOUT; SEIZURES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS; VIGABATRIN;

EID: 84874243165     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057445     Document Type: Article

References (35)

1. Elger CE, Schmidt D, (2008) Modern management of epilepsy: a practical approach. Epilepsy Behav 12: 501-39.
2. Kwan P, Brodie MJ, (2000) Early identification of refractory epilepsy. N Engl J Med 342: 314-319.
3. French JA, (2007) Refractory epilepsy: clinical overview. Epilepsia 48(Suppl 1): 3-7.
4. Temkin NR, (2001) Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 42: 515-524.
5. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, et al. (2004) Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 27: 1261-1273.
6. Holmes GL, Stafstrom CE, (2007) the Tuberous Sclerosis Study Group (2007) Tuberous Sclerosis Complex and epilepsy: recent developments and future challenges. Epilepsia 48: 617-630.
7. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele E, (2010) The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 51: 1236-1241.
8. Curatolo P, Verdechhia M, Bombardieri R, (2001) Vigabatrin for tuberous sclerosis complex. Brain Dev 23: 649-653.
9. Hancock E, Osborne JP, (1999) Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol 14: 71-74.
10. Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P, (2010) Early control of seizure improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol 14: 146-149.
11. Jozwiak S, Kotulska K, Domariska-Pakiela D, Lojsczyk B, Syczewska M, et al. (2011) Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 15: 424-431.
12. Ben-Menachem E, (2011) Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scan Suppl 192: 5-15.
13. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD, (2009) Vigabatrin: 2008 update. Epilepsia 50: 163-173.
14. Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schecter PJ, (1977) gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 29: 797-802.
15. Crino PB, Nathanson KL, Henske EP, (2006) The tuberous sclerosis complex. N Engl J Med 355: 1345-1356.
16. Wong M, (2010) Mammalian target of rapamycin (mTOR) inhibition as potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia 51: 27-36.
17. Galanopoulou AS, Gorter JA, Cepeda C, (2012) Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia 53: 1119-1130.
18. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, et al. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363: 1801-1811.
19. Uhlmann EJ, Wong M, Baldwin RL, Bajenaru ML, Onda H, et al. (2002) Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 52: 285-296.
20. Erbayat-Altay E, Zeng LH, Xu L, Gutmann D, Wong M, (2007) The natural history and treatment of epilepsy in a murine model of tuberous sclerosis. Epilepsia 48: 1470-1476.
21. Zeng LH, Xu L, Gutmann DH, Wong M, (2008) Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 63: 444-453.
22. Zhang B, Yang L, Konishi Y, Maeda N, Sakanaka M, et al. (2002) Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharm 42: 262-269.
23. Overstreet LS, Westbrook GL, (2001) Paradoxical reduction of synaptic inhibition by vigabatrin. J Neurophysiol 86: 596-603.
24. Wu Y, Wang W, Richerson GB, (2001) GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux via reversal of the GABA transporter. J Neurosci 21: 2630-2639.
25. Schulz DW, Macdonald RL, (1981) Barbiturate enhancement of GABA-mediated inhibition and activation of chloride conductance: correlation with anticonvulsant and anesthetic actions. Brain Res 209: 177-188.
26. Hertz E, Shargool M, Hertz L, (1986) Effects of barbiturates on energy metabolism by cultured astrocytes and neurons in the presence of normal and elevated concentrations of potassium. Neuropharmacol 25: 533-539.
27. Hertz L, Mukerji S, (1980) Diazepam receptors on mouse astrocytes in primary cultures: displacement by pharmacologically active concentrations of benzodiazepines or barbiturates. Can J Physiol Pharmacol 58: 217-220.
28. Zhang B, Wong M, (2012) Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat. Epilepsia 53: 506-511.
29. Zeng LH, Rensing NR, Wong M, (2009) The mammalian target of rapamycin (mTOR) signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29: 6964-6972.
30. Zeng LH, Ouyang Y, Gazit V, Cirrito JR, Jansen LA, et al. (2007) Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol Dis 28: 184-196.
31. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, et al. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14064.
32. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, et al. (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 28: 5422-5432.
33. Goto J, Talos DM, Klein P, Qin W, Chekaluk YI, et al. (2011) Regulable neural progenitor-specific TSC1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci USA 108: 1070-1079.
34. Carson RP, Van Nielen DL, Winzenburger PA, Ess K, (2012) Neuronal and glia abnormalities in TSC1-deficient forebrain and partial rescue by rapamycin. Neurobiol Dis. 45: 369-380.
35. Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulo AS, (2011) A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis 43: 322-328.